Technical Analysis for CRIS - Curis, Inc.

Grade Last Price % Change Price Change
B 12.21 2.86% 0.34
CRIS closed up 2.86 percent on Thursday, April 15, 2021, on 87 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical CRIS trend table...

Date Alert Name Type % Chg
Up 3 Days in a Row Strength 0.00%
Crossed Above 20 DMA Bullish 2.86%
20 DMA Resistance Bearish 7.39%
50 DMA Support Bullish 7.39%
Fell Below 20 DMA Bearish 12.85%
50 DMA Support Bullish 12.85%
MACD Bearish Signal Line Cross Bearish 6.17%
20 DMA Support Bullish 6.17%
Narrow Range Bar Range Contraction 3.21%
NR7 Range Contraction 3.21%
Older End-of-Day Signals for CRIS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 22 hours ago
Rose Above Previous Day's High about 23 hours ago
Up 3% about 23 hours ago
Up 2% about 23 hours ago
10 DMA Support about 24 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Curis, Inc. Description

Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Drugs Surgery Drug Discovery Lymphoma Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Carcinoma Cancer Cell Multiple Myeloma Cancer Therapeutics Protein Kinase Inhibitors Hematological Cancers Phosphoinositide 3 Kinase Inhibitor Lung Cancers Small Cell Lung Cancers Advanced Non Small Cell Lung Cancer Non Small Cell Lung Cancers Refractory Solid Tumors

Is CRIS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.44
52 Week Low 0.685
Average Volume 1,879,639
200-Day Moving Average 5.12
50-Day Moving Average 10.76
20-Day Moving Average 11.61
10-Day Moving Average 11.72
Average True Range 0.92
ADX 9.17
+DI 20.51
-DI 21.49
Chandelier Exit (Long, 3 ATRs ) 10.25
Chandelier Exit (Short, 3 ATRs ) 12.56
Upper Bollinger Band 12.69
Lower Bollinger Band 10.53
Percent B (%b) 0.78
BandWidth 18.60
MACD Line 0.30
MACD Signal Line 0.32
MACD Histogram -0.0215
Fundamentals Value
Market Cap 718.16 Million
Num Shares 58.8 Million
EPS -0.91
Price-to-Earnings (P/E) Ratio -13.37
Price-to-Sales 5.00
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.22
Resistance 3 (R3) 13.15 12.75 13.05
Resistance 2 (R2) 12.75 12.49 12.78 12.99
Resistance 1 (R1) 12.48 12.34 12.62 12.55 12.94
Pivot Point 12.08 12.08 12.15 12.11 12.08
Support 1 (S1) 11.81 11.82 11.95 11.88 11.48
Support 2 (S2) 11.41 11.67 11.44 11.43
Support 3 (S3) 11.14 11.41 11.37
Support 4 (S4) 11.21